TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06001151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients receive cadonilimab (10mg/kg) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients receive pemetrexed (500mg/m2) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
Study: NCT05759286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
Study: NCT04487353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor mechanism application developed with virtual reality technology (VRT-LMA)
Description: In phase I: VRT-LMA application was developed. (Female in lithotomy position, bony pelvis, flexion of the coccyx back about 2 cm and the Hodge plane were modeled as lines. The theory training to be given to the control group was prepared in accordance with the curriculum.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~III. In the second stage: the post-test and analyzes were performed after 5 weeks in both groups.
Study: NCT05521711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Commercially available powders or liquids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Commercially available powders or liquids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Commercially available powders or liquids
Study: NCT05631041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: participants in silymarin group will receive silymarin 140 mg once daily.
Study: NCT05462782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) Cone Coil
Description: The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) Sham Coil
Description: The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
Study: NCT06087471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention snack
Description: The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control Snack
Description: The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
Study: NCT05296070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine 150 µg/Kg
Description: Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine 75µg/Kg
Description: Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
Study: NCT05984173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E application
Description: patients received vitamin E inside the socket after extraction
Study: NCT04735796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：LM-102
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：LM-102
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：LM-102
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：LM-102
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：LM-102
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
Study: NCT05050500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg/Tab
Description: patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
Study: NCT05816460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)
Description: Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be delivered through an online platform called Sleepio (BigHealth Ltd)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Description: Sleep Hygiene Education (SHE) will be provided electronically
Study: NCT05187091

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Swallowing and submandibular sparing IMRT
Description: Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures \& submandibular gland sparing by SWOAR-IMRT
Study: NCT04990271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept ophthalmic injection
Description: Monthly injection of Conbercept from 0\~5 months
Study: NCT05642416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion of ropivacaine
Description: Continuous infusion of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent bolus of ropivacaine
Description: Intermittent bolus of ropivacaine
Study: NCT05987592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Education and WELLness with Migraine Group A
Description: Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Education and WELLness with Migraine Group B
Description: Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
Study: NCT05132855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
Study: NCT04696783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium Enteric-coated Tablets
Description: Nexium taken once every 2 days plus lifestyle adjustment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle adjustment
Description: Lifestyle adjustment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle adjustment
Description: Lifestyle adjustment
Study: NCT05891106

Intervention type: DEVICE
Intervention: Lotrafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses
Study: NCT06330675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Short-term bed-rest and immobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Bed-rest and immobility until the day-after procedure
Study: NCT06408350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Me, Alexis!
Description: Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Me, Alexis!
Description: Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Me, Alexis!
Description: Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression
Study: NCT05276960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol Pill
Description: Dose increments according to serum levels determined every 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Pill
Description: Dose increments according to serum levels determined every 2 months
Study: NCT06006637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
Study: NCT05119686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 1
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 1
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 2
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Solid Oral Capsule Placebo
Study: NCT06379529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NuvoAir clinical service
Description: Patients with COPD receiving usual care plus NuvoAir clinical services.
Study: NCT04418414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene therapy
Description: CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological
Description: G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
Study: NCT05859711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thyme honey mouth rinse
Description: oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline mouth rinse
Description: saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
Study: NCT06294691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Time of stem cell infusion
Description: Randomization of patients according to the time of stem cell infusion

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Time of stem cell infusion
Description: Randomization of patients according to the time of stem cell infusion
Study: NCT05580211

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem modulation device (stimulation Randomized)
Description: Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem modulation device (stimulation Randomized)
Description: Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem modulation device (stimulation-Open Label)
Description: Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
Study: NCT06568458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Specified Dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Specified Dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986278
Description: Specified dose on specified days
Study: NCT05968885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradetrusor Botox® (onabotulinumtoxinA) injection
Description: The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combine Mirabegron and Solifenacin.
Description: Combination pharmacotherapy
Study: NCT04665297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Guide for Monitoring Child Development
Description: Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
Study: NCT06712121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine plus venetoclax
Description: decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days
Study: NCT06731452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
Description: Online SMART is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~Stress Solutions extends the SMART principles to relevant domains of stress and resilience.
Study: NCT06728982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000mg of metformin twice daily by mouth
Study: NCT06728241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RecoVRy
Description: A mental health professional (VR therapist) will be together with the patient when VR treatment is provided. The VR therapist will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary
Study: NCT05777109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20090
Description: A human IgG2 monoclonal antibody with affinity and specificity for human RANKL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study: NCT06263439

Intervention type: DIAGNOSTIC_TEST
Intervention: Throat/buccal swab sample
Description: The study involves the genome detection of enteroviruses in throat or mouth swabs taken from children with a diagnosis of HFMD or herpangina. If positive, the precise type of enterovirus responsible will be identified by sequencing a viral genomic region.
Study: NCT05553093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide ih qw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: 6 IU ih qd
Study: NCT05395923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture
Description: The pressure application will be applied before the incision on the palate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Suture CTG -Control
Description: A graft will be taken from the palate before the procedure is applied.
Study: NCT06028165

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting based on conventional coronary angiography
Description: Revascularized coronary arteries are decided based on conventional coronary angiography (quantitative coronary angiography)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.
Description: Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.